Adrian Nikolas Mihut
About Adrian Nikolas Mihut
Adrian Nikolas Mihut is a Sales Specialist Oncology at Bristol Myers Squibb, with over five years of experience in the pharmaceutical industry, specializing in innovative cancer treatments.
Current Role at Bristol Myers Squibb
Adrian Nikolas Mihut is currently serving as a Sales Specialist Oncology at Bristol Myers Squibb. Based in Heidelberg und Umgebung, Adrian focuses on promoting innovative cancer treatments. His responsibilities include engaging with healthcare professionals and institutions to enhance the adoption of cutting-edge oncology therapies.
Previous Experience in Inflammation and Rheumatology
Before joining Bristol Myers Squibb, Adrian Nikolas Mihut worked at Gilead Sciences as a Therapeutic Specialist in the Inflammation division, specifically focusing on rheumatology. He held this position for a year from 2020 to 2021, working primarily in Würzburg und Umgebung, Deutschland. His role involved implementing therapeutic sales strategies and building strong relationships with healthcare providers.
Sales Representative at AbbVie Deutschland GmbH & Co. KG
Adrian Nikolas Mihut accumulated valuable experience while working as a Sales Representative at AbbVie Deutschland GmbH & Co. KG from 2018 to 2020. During his two-year tenure, he contributed to the development and execution of sales strategies, enhancing the company’s market presence in the pharmaceutical industry.
Education and Academic Background
Adrian Nikolas Mihut pursued his higher education at the Karlsruher Institut für Technologie (KIT), where he studied Biologie, allgemein. He graduated with a Master's degree, completing his studies in 2017 after three years of rigorous academic training. His educational background provides a strong foundation for his current role in the pharmaceutical sales industry.
Pharmaceutical Industry Experience
With over five years of experience in the pharmaceutical industry, Adrian Nikolas Mihut has a broad understanding of sales in the context of both inflammation and oncology sectors. His career has seen him operate in various regions, including Würzburg and Heidelberg, offering him a diverse perspective on market dynamics and healthcare needs.